Lexaria Bioscience (LEXX) Projected to Post Earnings on Monday

Lexaria Bioscience (NASDAQ:LEXX) is anticipated to announce its results before the market opens on Monday, April 13th. Analysts expect the company to announce earnings of ($0.0950) per share and revenue of $0.05 million for the quarter.

Lexaria Bioscience (NASDAQ:LEXX) last released its quarterly earnings data on Tuesday, January 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.14 million. Lexaria Bioscience had a negative return on equity of 226.58% and a negative net margin of 1,685.84%. On average, analysts expect Lexaria Bioscience to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexaria Bioscience Price Performance

NASDAQ LEXX opened at $1.04 on Monday. The stock has a market capitalization of $25.89 million, a PE ratio of -1.86 and a beta of 0.48. Lexaria Bioscience has a 12-month low of $0.46 and a 12-month high of $1.69. The company has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $0.86.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on LEXX shares. Wall Street Zen downgraded shares of Lexaria Bioscience from a “hold” rating to a “sell” rating in a report on Sunday, December 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Lexaria Bioscience in a research report on Monday, December 29th. Finally, HC Wainwright cut their target price on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating on the stock in a report on Friday, December 26th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lexaria Bioscience has an average rating of “Hold” and a consensus target price of $1.50.

Institutional Trading of Lexaria Bioscience

An institutional investor recently raised its position in Lexaria Bioscience stock. Geode Capital Management LLC increased its position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) by 25.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 219,718 shares of the company’s stock after buying an additional 44,939 shares during the period. Geode Capital Management LLC owned 0.88% of Lexaria Bioscience worth $136,000 at the end of the most recent reporting period. 13.06% of the stock is currently owned by institutional investors.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.